Shilpa Medicare Limited

NSEI:SHILPAMED Stock Report

Market Cap: ₹47.8b

Shilpa Medicare Management

Management criteria checks 2/4

Shilpa Medicare's CEO is Vishnukanth Bhutada, appointed in Aug 2022, has a tenure of 1.75 years. total yearly compensation is ₹35.00M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 8.87% of the company’s shares, worth ₹4.24B. The average tenure of the management team and the board of directors is 2.5 years and 2.7 years respectively.

Key information

Vishnukanth Bhutada

Chief executive officer

₹35.0m

Total compensation

CEO salary percentage100.0%
CEO tenure1.8yrs
CEO ownership8.9%
Management average tenure2.5yrs
Board average tenure2.7yrs

Recent management updates

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Recent updates

What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Apr 12
What Shilpa Medicare Limited's (NSE:SHILPAMED) 27% Share Price Gain Is Not Telling You

Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Feb 21
Shilpa Medicare Limited's (NSE:SHILPAMED) Shares Climb 28% But Its Business Is Yet to Catch Up

Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

Jan 02
Shilpa Medicare (NSE:SHILPAMED) Takes On Some Risk With Its Use Of Debt

These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Jul 17
These 4 Measures Indicate That Shilpa Medicare (NSE:SHILPAMED) Is Using Debt Extensively

Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Mar 17
Shilpa Medicare (NSE:SHILPAMED) Seems To Be Using A Lot Of Debt

Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Sep 22
Increases to CEO Compensation Might Be Put On Hold For Now at Shilpa Medicare Limited (NSE:SHILPAMED)

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Sep 07
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Aug 14
Shilpa Medicare's (NSE:SHILPAMED) Dividend Will Be ₹1.10

Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Jan 27
Here's Why Shilpa Medicare (NSE:SHILPAMED) Is Weighed Down By Its Debt Load

Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Sep 21
Shareholders May Not Be So Generous With Shilpa Medicare Limited's (NSE:SHILPAMED) CEO Compensation And Here's Why

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jun 17
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

May 31
If You Like EPS Growth Then Check Out Shilpa Medicare (NSE:SHILPAMED) Before It's Too Late

Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Mar 07
Shilpa Medicare Limited's (NSE:SHILPAMED) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Feb 20
Shilpa Medicare Limited (NSE:SHILPAMED) Analysts Are Reducing Their Forecasts For Next Year

Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Jan 26
Does Shilpa Medicare (NSE:SHILPAMED) Have A Healthy Balance Sheet?

Here's Why I Think Shilpa Medicare (NSE:SHILPAMED) Is An Interesting Stock

Jan 14
Here's Why I Think Shilpa Medicare (NSE:SHILPAMED) Is An Interesting Stock

Shilpa Medicare (NSE:SHILPAMED) Shareholders Have Enjoyed A 54% Share Price Gain

Jan 03
Shilpa Medicare (NSE:SHILPAMED) Shareholders Have Enjoyed A 54% Share Price Gain

Could The Shilpa Medicare Limited (NSE:SHILPAMED) Ownership Structure Tell Us Something Useful?

Dec 22
Could The Shilpa Medicare Limited (NSE:SHILPAMED) Ownership Structure Tell Us Something Useful?

Is There More To The Story Than Shilpa Medicare's (NSE:SHILPAMED) Earnings Growth?

Dec 11
Is There More To The Story Than Shilpa Medicare's (NSE:SHILPAMED) Earnings Growth?

How Much Are Shilpa Medicare Limited (NSE:SHILPAMED) Insiders Taking Off The Table?

Nov 30
How Much Are Shilpa Medicare Limited (NSE:SHILPAMED) Insiders Taking Off The Table?

How Is Shilpa Medicare's (NSE:SHILPAMED) CEO Compensated?

Nov 16
How Is Shilpa Medicare's (NSE:SHILPAMED) CEO Compensated?

Earnings Release: Here's Why Analysts Cut Their Shilpa Medicare Limited (NSE:SHILPAMED) Price Target To ₹611

Nov 04
Earnings Release: Here's Why Analysts Cut Their Shilpa Medicare Limited (NSE:SHILPAMED) Price Target To ₹611

Could The Market Be Wrong About Shilpa Medicare Limited (NSE:SHILPAMED) Given Its Attractive Financial Prospects?

Oct 27
Could The Market Be Wrong About Shilpa Medicare Limited (NSE:SHILPAMED) Given Its Attractive Financial Prospects?

CEO Compensation Analysis

How has Vishnukanth Bhutada's remuneration changed compared to Shilpa Medicare's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

-₹7m

Sep 30 2023n/an/a

-₹119m

Jun 30 2023n/an/a

-₹321m

Mar 31 2023₹35m₹35m

-₹325m

Dec 31 2022n/an/a

₹51m

Sep 30 2022n/an/a

₹213m

Jun 30 2022n/an/a

₹599m

Mar 31 2022₹97m₹16m

₹607m

Dec 31 2021n/an/a

₹395m

Sep 30 2021n/an/a

₹376m

Jun 30 2021n/an/a

₹631m

Mar 31 2021₹97m₹16m

₹1b

Dec 31 2020n/an/a

₹2b

Sep 30 2020n/an/a

₹2b

Jun 30 2020n/an/a

₹2b

Mar 31 2020₹99m₹10m

₹2b

Dec 31 2019n/an/a

₹1b

Sep 30 2019n/an/a

₹1b

Jun 30 2019n/an/a

₹944m

Mar 31 2019₹75m₹10m

₹1b

Dec 31 2018n/an/a

₹1b

Sep 30 2018n/an/a

₹1b

Jun 30 2018n/an/a

₹1b

Mar 31 2018₹81m₹16m

₹1b

Compensation vs Market: Vishnukanth's total compensation ($USD419.30K) is above average for companies of similar size in the Indian market ($USD271.33K).

Compensation vs Earnings: Vishnukanth's compensation has been consistent with company performance over the past year.


CEO

Vishnukanth Bhutada (61 yo)

1.8yrs

Tenure

₹35,000,000

Compensation

Mr. Vishnukanth Chaturbhuj Bhutada, B. Pharm. serves as the Managing Director of Shilpa Medicare Limited since August 11, 2022 . Mr. Bhutada joined Shilpa Medicare Limited in November 1987.He serves as th...


Leadership Team

NamePositionTenureCompensationOwnership
Vishnukanth Bhutada
MD & Director1.8yrs₹35.00m8.87%
₹ 4.2b
Alpesh Dalal
Chief Financial Officer3yrs₹13.20m0.0023%
₹ 1.1m
Sharath Kalakota
VP of Projects & Operations and Whole-time Directorno data₹14.50mno data
Ritu Tiwary
Company Secretary & Compliance Officer2yrs₹4.50mno data
Jayant Karajgi
Chief Operating Officer of Formulationsno data₹22.95mno data
Awez Pathan
Vice Presidentno data₹12.40mno data
Pramod Kumar
Senior Vice President of Technicalno data₹6.06mno data
P. V. Rao
Chief Human Resource Officerno datano datano data
Vinay Konaje
Business Head of Biologicsno datano datano data
Rajyashri Ramakrishnan
Chief Scientific Officer of Biologicalsno data₹46.30mno data
Prakash Venkataraman
Senior VP & Global Business Head of API Business3.3yrs₹19.55mno data
K. Honneshaiah
Head Operation of APIno datano datano data

2.5yrs

Average Tenure

56yo

Average Age

Experienced Management: SHILPAMED's management team is considered experienced (2.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Vishnukanth Bhutada
MD & Director36.5yrs₹35.00m8.87%
₹ 4.2b
Sharath Kalakota
VP of Projects & Operations and Whole-time Director4.6yrs₹14.50mno data
Arvind Vasudeva
Non-Executive Independent Director2.7yrs₹3.00mno data
Kamal Sharma
Non-Executive Independent Director1.8yrs₹2.25mno data
Hetal Gandhi
Non-Executive Independent Director2.7yrs₹4.00mno data
Om Inani
Non-Executive Chairman36.2yrs₹250.00k3.3%
₹ 1.6b
Anita Bandyopadhyay
Independent Women Director1.8yrs₹1.20mno data

2.7yrs

Average Tenure

61yo

Average Age

Experienced Board: SHILPAMED's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.